Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

被引：0

作者：

Khattak, Adnan

Weber, Jeffrey S.

Meniawy, Tarek

Taylor, Matthew H.

Ansstas, George

Kim, Kevin B.

McKean, Meredith

Long, Georgina V.

Sullivan, Ryan J.

Faries, Mark B.

Tran, Thuy

Cowey, Charles Lance

Medina, Theresa Michelle

Segar, Jennifer Margaret

Atkinson, Victoria

Gibney, Geoffrey Thomas

Luke, Jason J.

Buchbinder, Elizabeth Iannotti

Meehan, Robert S.

Carlino, Matteo S.

机构：

[1] One Clin Res, Perth, WA, Australia

[2] Edith Cowan Univ, Perth, WA, Australia

[3] NYU Sch Med, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Earle Chiles Res Inst, Portland, OR USA

[6] Washington Univ Oncol, St Louis, MO USA

[7] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA

[8] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[9] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[10] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[11] Massachusetts Gen Hosp, Boston, MA USA

[12] Angeles Clin & Res Inst, Los Angeles, CA USA

[13] Yale New Haven Hosp, New Haven, CT USA

[14] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA

[15] Univ Colorado, Aurora, CO USA

[16] Univ Arizona, Ctr Canc, Tucson, AZ USA

[17] Princess Alexandra Hosp, Woolloongabba, Qld, Australia

[18] Univ Queensland, Woolloongabba, Qld, Australia

[19] Lombardi Comprehens Canc Ctr, Washington, DC USA

[20] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[21] Dana Farber Canc Inst, Boston, MA USA

[22] Moderna Therapeut, Cambridge, MA USA

[23] Univ Sydney, Melanoma Inst Australia, Westmead & Blacktown Hosp, Sydney, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA9503

引用

页数：1

共 50 条

[1] Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
Khattak, Adnan
Weber, Jeffrey S.
Meniawy, Tarek
Taylor, Matthew H.
Ansstas, George
Kim, Kevin B.
McKean, Meredith
Long, Georgina V.
Sullivan, Ryan J.
Faries, Mark B.
Tran, Thuy
Cowey, Charles Lance
Medina, Theresa Michelle
Segar, Jennifer Margaret
Atkinson, Victoria
Gibney, Geoffrey Thomas
Luke, Jason J.
Buchbinder, Elizabeth Iannotti
Meehan, Robert S.
Carlino, Matteo S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9503 - LBA9503
[2] Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Sullivan, R. J.
Lu, M.
Koppolu, S.
Weber, J. S.
Carlino, M. S.
Khattak, M. A.
Ansstas, G.
Taylor, M. H.
Mckean, M.
Long, G. V.
Faries, M. B.
Luke, J. J.
Sehgal, V.
Rao, A.
Mao, H.
Guo, J.
Brown, M.
Meehan, R.
Feldman, I.
Srinivasan, L.
ANNALS OF ONCOLOGY, 2024, 35 : S727 - S728
[3] Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
Weber, Jeffrey S.
Khattak, Muhammad Adnan
Carlino, Matteo S.
Meniawy, Tarek
Taylor, Matthew H.
Ansstas, George
Kim, Kevin B.
McKean, Meredith
Sullivan, Ryan J.
Faries, Mark B.
Tran, Thuy
Cowey, Charles Lance
Medina, Theresa
Segar, Jennifer Margaret
Atkinson, Victoria
Gibney, Geoffrey Thomas
Luke, Jason J.
Buchbinder, Elizabeth Iannotti
Long, Georgina V.
Meehan, Robert S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9512 - LBA9512
[4] Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Weber, Jeffrey S.
Carlino, Matteo S.
Khattak, Adnan
Meniawy, Tarek
Ansstas, George
Taylor, Matthew H.
Kim, Kevin B.
McKean, Meredith
Long, Georgina, V
Sullivan, Ryan J.
Faries, Mark
Tran, Thuy T.
Cowey, C. Lance
Pecora, Andrew
Shaheen, Montaser
Segar, Jennifer
Medina, Theresa
Atkinson, Victoria
Gibney, Geoffrey T.
Luke, Jason J.
Thomas, Sajeve
Buchbinder, Elizabeth, I
Healy, Jane A.
Huang, Mo
Morrissey, Manju
Feldman, Igor
Sehgal, Vasudha
Robert-Tissot, Celine
Hou, Peijie
Zhu, Lili
Brown, Michelle
Aanur, Praveen
Meehan, Robert S.
Zaks, Tal
LANCET, 2024, 403 (10427): : 632 - 644
[5] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Long, Georgina, V
Luke, Jason J.
Khattak, Muhammad A.
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Mohr, Peter
Dummer, Reinhard
Gershenwald, Jeffrey E.
Yoon, Charles H.
Wu, Xi Lawrence
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Ascierto, Paolo A.
LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
[6] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
Long, G. V.
Luke, J.
Khattak, M. A.
de la Cruz Merino, L.
Del Vecchio, M.
Rutkowski, P.
Spagnolo, F.
Mackiewicz, J.
Chiarion-Sileni, V.
Kirkwood, J. M.
Robert, C.
Grob, J. J.
de Galitiis, F.
Schadendorf, D.
Carlino, M. S.
Wu, L.
Fukunaga-Kalabis, M.
Krepler, C.
Eggermont, A. M. M.
Ascierto, P. A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 95 - 95
[7] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
[8] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
Long, Georgina V.
Luke, Jason J.
Khattak, Muhammad
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Wu, Larry
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[9] Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study
Luke, Jason J.
Ascierto, Paolo Antonio
Khattak, Muhammad Adnan
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M. M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Wu, Larry
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[10] Adjuvant radiotherapy for pathologic T3 prostate cancer: Results of a randomized, prospective clinical trial with metastasis-free survival endpoint
Thompson, IM
Tangen, C
Miller, GJ
Lucia, MS
Troyer, DA
Paradelo, J
Chin, JL
Messing, EM
Canby-Hagino, ED
Forman, J
Crawford, ED
JOURNAL OF UROLOGY, 2005, 173 (04): : 451 - 452

← 1 2 3 4 5 →